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Supplemental oxygen is frequently administered to patients with acute 
respiratory distress syndrome (ARDS), including ARDS secondary to viral 
illness such as coronavirus disease 19 (COVID-19). An up-to-date 
understanding of how best to target this therapy (e.g. arterial partial pressure 
of oxygen (PaO2) or peripheral oxygen saturation (SpO2) aim) in these 
patients is urgently required. 
Objectives 
To address how oxygen therapy should be targeted in adults with ARDS 
(particularly ARDS secondary to COVID-19 or other respiratory viruses) and 
requiring mechanical ventilation in an intensive care unit, and the impact 
oxygen therapy has on mortality, days ventilated, days of catecholamine use, 
requirement for renal replacement therapy, and quality of life. 
Search methods 
We searched the Cochrane COVID-19 Study Register, CENTRAL, MEDLINE, 
and Embase from inception to 15 May 2020 for ongoing or completed 
randomized controlled trials (RCTs). 
Selection criteria 
Two review authors independently assessed all records in accordance with 
standard Cochrane methodology for study selection. 
We included RCTs comparing supplemental oxygen administration (i.e. 
different target PaO2 or SpO2 ranges) in adults with ARDS and receiving 
mechanical ventilation in an intensive care setting. We excluded studies 
exploring oxygen administration in patients with different underlying diagnoses 
or those receiving non-invasive ventilation, high-flow nasal oxygen, or oxygen 
via facemask. 
Data collection and analysis 
One review author performed data extraction, which a second review author 
checked. We assessed risk of bias in included studies using the Cochrane 
'Risk of bias' tool. We used the GRADE approach to judge the certainty of the 
evidence for the following outcomes; mortality at longest follow-up, days 
ventilated, days of catecholamine use, and requirement for renal replacement 
therapy. 
Main results 
We identified one completed RCT evaluating oxygen targets in patients with 
ARDS receiving mechanical ventilation in an intensive care setting. The study 
randomized 205 mechanically ventilated patients with ARDS to either 
conservative (PaO2 55 to 70 mmHg, or SpO2 88% to 92%) or liberal (PaO2 90 
to 105 mmHg, or SpO2 ≥ 96%) oxygen therapy for seven days. 
Overall risk of bias was high (due to lack of blinding, small numbers of 
participants, and the trial stopping prematurely), and we assessed the 
certainty of the evidence as very low. The available data suggested that 
mortality at 90 days may be higher in those participants receiving a lower 
oxygen target (odds ratio (OR) 1.83, 95% confidence interval (CI) 1.03 to 
3.27). There was no evidence of a difference between the lower and higher 
target groups in mean number of days ventilated (14.0, 95% CI 10.0 to 18.0 
versus 14.5, 95% CI 11.8 to 17.1); number of days of catecholamine use (8.0, 
95% CI 5.5 to 10.5 versus 7.2, 95% CI 5.9 to 8.4); or participants receiving 
renal replacement therapy (13.7%, 95% CI 5.8% to 21.6% versus 12.0%, 95% 
CI 5.0% to 19.1%). Quality of life was not reported. 
Authors' conclusions 
We are very uncertain as to whether a higher or lower oxygen target is more 
beneficial in patients with ARDS and receiving mechanical ventilation in an 
intensive care setting. We identified only one RCT with a total of 205 
participants exploring this question, and rated the risk of bias as high and the 
certainty of the findings as very low. Further well-conducted studies are 
urgently needed to increase the certainty of the findings reported here. This 
review should be updated when more evidence is available. 
Plain language summary 
Approaches to guiding oxygen therapy 
in adult intensive care patients with 
acute respiratory distress syndrome 
Background 
Acute respiratory distress syndrome (ARDS) is a very severe breathing 
problem with a high mortality rate (chance of dying). It has many potential 
causes, including viral infections such as COVID-19, and there are no specific 
treatments for it except for giving patients oxygen via a ventilator (artificial 
breathing machine) on an intensive care unit, often for long periods of time. 
However, large amounts of oxygen (either a high concentration of oxygen or 
oxygen administered for a long period of time) are associated with increased 
harm due to other illnesses (e.g. heart attack or stroke). 
What did we want to find out? 
We wanted to know whether patients with severe lung problems (ARDS) 
would do better (including less chance of dying) if they received higher or 
lower amounts of oxygen whilst they were on a ventilator in intensive care. 
Methods 
We searched major medical databases up to 15 May 2020 for clinical trials 
studying oxygen use in adult patients with ARDS in intensive care units. We 
only searched for studies with the sickest patients, that is those who needed 
help with their breathing through a breathing tube that was connected to an 
artificial breathing machine. We did not restrict the search by language of 
publication. 
In addition to extracting and analysing the data from any studies that met 
these criteria, we also assessed the risk of bias (fairness) and the certainty 
(confidence) of the findings. 
Results 
We included only one study (205 participants) in the review. Patients with 
ARDS and receiving oxygen through a breathing tube in an intensive care unit 
may have a higher chance of death if they receive lower amounts of oxygen 
compared to receiving much higher amounts of oxygen, but the evidence is 
very uncertain. 
Certainty of evidence 
Our certainty (confidence) in these findings is very low as data were only 
available from one study that had only a small number of participants, and 
was stopped earlier than anticipated because of safety concerns. We are 
therefore unable to definitively say whether giving more or less oxygen to 
ARDS patients is helpful. 
 
Summary of findings 
Summary of findings 1 
Oxygen targets in the intensive care unit during mechanical ventilation 
for acute respiratory distress syndrome 
Patients or population: adult (≥ 18 years of age) patients receiving mechanical ventilation (via 
either an endotracheal tube or a tracheostomy) for acute respiratory distress syndrome (ARDS) 
(Berlin definition), including ARDS secondary to COVID-19 or other viruses 
Settings: intensive care units in: France 
Intervention: ‘conservative’ oxygen target: PaO2 55 - 70 mmHg or SpO2 88 - 92% 
Comparison: ‘liberal’ oxygen target: PaO2 90 - 105 mmHg or SpO2 ≥96% 
Outcomes 
Anticipated absolute effects 













Mortality at longest 
follow-up (follow-
up: 90 days) 
304 per 1,000 444 per 1000 








Number of days 
ventilated 
Mean number of 
days ventilated 
was 14.5 days 
MD 0.5 days 
fewer (0.98 








(scale from 0 to 28, 
days of 
catecholamine use) 
Mean duration of 
catecholamine 
use was 7.2 days 
MD 0.8 days 
more (0.52 more 







therapy (follow-up: 6 
days) 
98 per 1,000 101 per 1,000 








Quality of life - - - 0 - 
CI: confidence interval; MD: mean difference; OR: odds ratio 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of 
effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in 
the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in 
the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
aDowngraded due to serious concerns about risk of bias. High risk of selection bias (open-label and unblinded) 
and early stopping bias (stopped prematurely). 
bDowngraded two levels due to very serious concerns about imprecision. Only one study with a low overall total 
number of participants included in the review. 
Background 
Brief description of the condition/issue under 
consideration 
COVID-19, an acute respiratory disease caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), can cause acute respiratory failure 
with persistent hypoxaemia. A surge in demand for mechanical ventilation has 
resulted from the international spread of this novel virus, which has stretched 
and exceeded national critical care capacity in some countries (Grasselli 
2020). Research on oxygen therapy in critically unwell ventilated patients is 
limited and conflicting. A previous Cochrane Review concluded that 
considerable uncertainty remains about how oxygen therapy should be 
targeted in all patients admitted to intensive care units; however, this review 
looked at all methods of oxygen therapy (including non-invasive ventilation) 
for any cause of critical illness, including traumatic brain injury, chronic 
obstructive pulmonary disease (COPD), and out-of-hospital cardiac arrest 
(Barbateskovic 2019). Such a diverse and varied group of pathologies are 
likely to respond best to a variety of different ventilation and oxygenation 
strategies; COVID-19-induced lung disease is itself a novel and unusual 
cause of respiratory failure and one that has already been noted to behave 
differently to previously considered critical illness clinical syndromes (Gattinoni 
2020; Roberts 2020). Acute respiratory distress syndrome (ARDS, the new 
term for severe acute lung injury), which can be secondary to viral illnesses 
such as COVID-19 or other non-viral causes, is associated with very high 
morbidity and mortality. A number of therapeutic agents have been trialled 
without successfully improving long-term outcomes, including aerosolised 
prostacyclins (Afshari 2017), inhaled nitric oxide (Afshari 2010), 
corticosteroids and surfactants (Lewis 2019), and no specific treatments are 
currently available or in widespread clinical use. Furthermore, these patients 
often require prolonged durations of mechanical ventilation and oxygen 
therapy, which also both carry their own risks (Andersen 2016). Despite 
previous reviews studying oxygen use in the critical care unit, it remains 
unclear how best to target oxygen administration in mechanically ventilated 
patients with ARDS, or in the subgroup of these patients with viral-induced 
lung injury (such as COVID-19). 
Description of the intervention 
Patients with respiratory failure severe enough to necessitate mechanical 
ventilation also require supplementary oxygen to treat their hypoxaemia. The 
amount of oxygen administered may be described either as a percentage or 
as a fraction of the inspired gas mixture, for example a patient being 
administered normal room air would receive approximately 21% oxygen or 
FiO2 (fraction of inspired oxygen = 0.21). The clinical team will titrate the 
FiO2 being administered to achieve a particular level of oxygenation in the 
patient’s blood, usually by targeting either continuously monitored peripheral 
oxygen saturations (SpO2) or intermittent measurement of arterial partial 
pressures of oxygen (PaO2), which can both be easily monitored in the 
intensive care unit.  
How the intervention might work 
The body has no way of storing oxygen, so even short periods of hypoxaemia 
can rapidly cause irreversible harm, including organ failure (e.g. hypoxic brain 
injury, stroke, myocardial infarction, acute kidney injury) or death. Clinicians 
have historically tended towards administering more oxygen to avoid these 
risks (Leach 2002). However, hyperoxaemia is also increasingly recognized 
as being associated with more complications (particularly pulmonary 
complications) and worse outcomes in a number of other clinical contexts, 
including critical illness, cardiac disease (e.g. myocardial infarction), neonatal 
resuscitation, and stroke (Martin 2013). As well as its direct effects on the lung 
(e.g. absorption atelectasis or fibrosis), hyperoxaemia is thought to increase 
systemic production of reactive oxygen species (ROS) and pro-inflammatory 
cytokines, possibly worsening outcomes in pro-inflammatory conditions such 
as viral illnesses that are thought to induce a ‘cytokine storm’ (including 
COVID-19). This is also one potential mechanism by which coronavirus-
induced ARDS might respond differently to other forms of ARDS. Although 
supplemental oxygen administration is now recognized as being a double-
edged sword in critically ill patients with ARDS, the optimal oxygenation target 
(i.e. maximizing benefits whilst minimizing the harms of both hypoxia and 
hyperoxia) in these patients is unknown. It is also unknown whether the 
optimal oxygen regimen depends on the underlying aetiology of the ARDS. 
Objectives 
To address how oxygen therapy should be targeted in adults with ARDS 
(particularly ARDS secondary to COVID-19 or other respiratory viruses) and 
requiring mechanical ventilation in an intensive care unit, and the impact 
oxygen therapy has on mortality, days ventilated, days of catecholamine use, 
requirement for renal replacement therapy, and quality of life. 
Methods 
Criteria for considering studies for this review 
Prespecified eligibility criteria were as follows. 
Study design 
Randomized controlled trials, including cluster-randomized and cross-over 
trials. 
Minimum study duration 
There was no minimum study duration. 
Population 
We included studies looking at adult (≥ 18 years of age) patients admitted to 
an intensive care unit or other level 3 area and receiving mechanical 
ventilation (via either an endotracheal tube or a tracheostomy) for ARDS 
(Berlin definition), including ARDS secondary to COVID-19 or other viruses. 
We excluded studies where participants received non-invasive ventilation, 
high-flow nasal oxygen, hyperbaric oxygen, cardiac bypass, or extra-corporeal 
membrane oxygenation (ECMO). 
Intervention 
‘Liberal’ oxygen, defined as relative to a comparable ‘conservative’ or control 
group to maximize inclusion of studies. This could consist of targeting higher 
SpO2, PaO2, or any combination of these where the study intention was to 
compare groups receiving different amounts of oxygen, in the opinion of the 
review authors. 
Comparator(s) 
‘Conservative’ oxygen, that is the study intention (in the opinion of the review 
authors) was to compare giving a lower amount of oxygen to this group than 
the intervention arm in the same trial. This may have been targeting mild 
hyperoxaemia (but relatively less hyperoxaemia than the interventional group 
in a particular study), normoxaemia, or hypoxaemia. 
Outcome(s) 
Critical outcome measures 
• Mortality at longest available follow-up 
• Number of days ventilated 
• Requirement for inotropic support 
• Requirement for renal replacement therapy 
• Quality of life (any recognized scale as reported by the trialists) 
We included studies in the review irrespective of whether measured outcome 
data were reported in a ‘useable’ way. 
Search methods for identification of studies 
We adhered to the following methods prespecified in the protocol 
(see Appendix 1): an Information Specialist (Janne Vendt) designed and 
conducted all searches, which were informed by the authors as content 
experts and independently peer reviewed by a second Information Specialist 
(Robin Featherstone). 
Electronic databases 
We searched the Cochrane COVID-19 Study Register, the Cochrane Central 
Register of Controlled Trials (CENTRAL), MEDLINE, and Embase from 
inception to 15 May 2020 (Appendix 2). 
Other searches 
We handsearched bibliographic references from the included studies without 
any language restrictions. 
Screening 
Two review authors (AC, AO) with expertise in systematic reviewing 
independently screened all titles and abstracts for potential eligibility and 
reviewed the full texts for inclusion in the review. Any discrepancies were 
resolved by consensus. A third review author was available for consultation if 
consensus could not be reached, but this was not required. 
We recorded the reasons for exclusion for all studies excluded after full-text 
review (see Characteristics of excluded studies). 
Inclusion of non-English language studies 
We considered abstracts and full texts from published articles in any language 
for inclusion. 
We planned for the methods of all potentially eligible non-English language 
abstracts to be translated for screening, and for the full texts of any abstracts 
that progressed to full-text review to be translated; however, this was not 
necessary. 
Data collection and analysis 
We adhered to the following methods as prespecified in the protocol 
(see Appendix 1). 
Data management 
One review author (AC) extracted data from the included studies into Review 
Manager (RevMan) Version 5.3, which another review author (AO) 
independently checked for accuracy. 
Data extraction 
We extracted the following information. 
• Study design (including methods, location, sites, groups) 
• Setting 
• Participant characteristics (age, gender, and disease severity using an 
appropriate critical illness score, e.g. Sequential Organ Failure 
Assessment (SOFA), which is a widely validated score that has been 
developed to assess the acute morbidity of critical illness) (Lambden 
2019) 
• Intervention characteristics (PaO2, SpO2 or FiO2 used in each study to 
set interventional group targets) 
• Comparator characteristics 
• Outcomes assessed 
• Numerical data for outcomes of interest 
'Risk of bias' assessment 
Two review authors (AC, AO) used the Cochrane 'Risk of bias' tool to 
independently assess risk of bias of the included studies based on the 
following domains. 
• Sequence generation (selection bias) 
• Allocation concealment (selection bias) 
• Blinding of participants, personnel, and outcome assessors 
(performance and detection bias) 
• Incomplete outcome data (attrition bias) 
• Selective outcome reporting (reporting bias) 
• Other potential sources of bias 
Any discrepancies would have been resolved by discussion or by involving a 
third review author where required. 
Contacting study authors 
It was not necessary to contact study authors for missing data, as all data 
required to complete the review were available within the published trial 
reports and supplementary files. 
Measures of treatment effect 
We assessed continuous outcomes as mean difference (MD) with 95% 
confidence intervals (CI). If continuous outcome data were reported using 
different scales, we assessed these outcomes as standardized mean 
differences (SMD) and 95% CI.  We assessed dichotomous outcomes as 
odds ratios (ORs) with 95% CIs. 
Assessment of heterogeneity 
We had planned to inspect forest plots and use the I2 statistic to quantify 
possible heterogeneity (I2 statistic > 50% to signify substantial heterogeneity), 
but this was not possible due to the small number of included studies. 
Assessment of reporting biases 
We did not formally investigate assessment of reporting bias due to the small 
number of included studies. 
Data synthesis 
We had planned to combine studies with a random-effects model; however, 
this could not be performed due to the lack of available data. 
Subgroup analyses 
We did not perform subgroup analysis because we found insufficient studies 
to do so. If appropriate data had been available (i.e. multiple included studies 
with at least one relevant to the appropriate comparison group), we would 
have performed a subgroup analysis for any studies specifically reporting on 
viral-induced ARDS. 
Sensitivity analyses 
A sensitivity analysis was not planned for this review. 
GRADE 
We employed the GRADE approach to interpret findings, and 
used GRADEpro GDT to create 'Summary of findings' tables as suggested in 
the Cochrane Handbook for Systematic Reviews of Interventions when results 
of randomized controlled trials are available (Schünemann 2019). These 
tables provide outcome-specific information concerning the overall quality of 
evidence from the included study. We used this approach to assess the 
certainty of all reported outcomes. 
Results 
Description of studies 
Results of the search 
The initial searches yielded a total of 5125 results after removal of 405 
duplicates. Following title and abstract review, three potentially eligible 
records were identified. On reviewing the full texts of these records, two were 
excluded for not meeting the inclusion criteria (see Characteristics of excluded 
studies). Consequently, only one study was eligible for inclusion in the review 
(see Characteristics of included studies). The study flow diagram is shown 
in Figure 1. 
Included studies 
Only one study met all of our inclusion criteria (Barrot 2020). This 
prospectively registered randomized controlled trial, conducted across 13 
intensive care units in France, assigned participants with ARDS (Berlin 
definition) who had been mechanically ventilated (for less than 12 hours by 
the time of enrolment) to receive either conservative oxygen therapy (to target 
either PaO2 55 to 70 mmHg, or SpO2 88% to 92%) or liberal oxygen therapy 
(target PaO2 90 to 105 mmHg, or SpO2 ≥ 96%) for 7 days. The trial was 
stopped prematurely by the data and safety monitoring board due to safety 
concerns after the enrolment of 205 out of the planned 850 participants. The 
conservative oxygen group (n = 99) had a mean age of 63, mean SOFA score 
of 9.3, and were 66% male; the liberal oxygen group (n = 102) had a mean 
age of 63.5, mean SOFA of 8.9, and were 62.7% male. 
Although the initial ventilation strategy was the same in both groups except for 
the amount of oxygen administered (volume-assist control mode with tidal 
volumes of 6 mL per kg of predicted body weight), the settings for mechanical 
ventilation including positive end-expiratory pressure (PEEP) (and also timing 
of prone positioning and use of neuromuscular blockade) were coupled to the 
PF ratio (PaO2/FiO2) in each group by the protocol. The FiO2 could also be 
altered at the clinician’s discretion for procedures or transfers, but oxygenation 
was not systematically adjusted for routine tracheal suctioning. 
We found no completed studies specifically looking at viral-induced ARDS, 
including ARDS associated with COVID-19. 
Excluded studies 
On reviewing the full texts, two records were excluded for not meeting the 
inclusion criteria. Both were ongoing studies that were not specifically 
investigating oxygen targets in ARDS patients undergoing invasive 
mechanical ventilation in an intensive care setting (i.e. the wrong population) 
(ChiCTR2000032456; NCT03174002). 
Risk of bias in included studies 
The overall risk of bias for the one included study was high (see Figure 2 for 
individual domain judgements), as the trial was open-label and also stopped 
early after a pre-planned trial safety committee meeting (criteria for stopping 
were not specified). 
Effects of interventions 
Mortality at longest available follow-up 
The longest reported follow-up for mortality was at 90 days: 44 of the 99 
participants in the lower-target group died compared to 31 of the 102 in the 
higher-target group (OR 1.83, 95% confidence interval (CI) 1.03 to 3.27). 
Number of days ventilated 
The mean number of days ventilated in the lower-target group was 14.0 (95% 
CI 10.0 to 18.0) compared to 14.5 (95% CI 11.8 to 17.1) in the higher-target 
group. Although all participants were initially intubated and undergoing 
invasive ventilation, for follow-up purposes, mechanical ventilation was 
defined as including non-invasive ventilation and high-flow nasal oxygen as 
well as invasive ventilation. 
Requirement for inotropic support 
The mean number of days of catecholamine use in the lower-target group was 
8.0 (95% CI 5.5 to 10.5) compared to 7.2 (95% CI 5.9 to 8.4) in the higher-
target group. 
Requirement for renal replacement therapy 
At day 6, 10 of the 99 participants in the lower-target group were receiving 
renal replacement therapy (13.7%, 95% CI 5.8% to 21.6%) compared to 10 of 
102 participants in the higher-target group (12.0%, 95% CI 5.0% to 19.1%). 
Quality of life 
Quality of life was not reported in the included study. 
Discussion 
Summary of main findings 
The aim of this review was to assess how oxygen therapy should be targeted 
in patients with ARDS (particularly ARDS secondary to COVID-19) and 
requiring mechanical ventilation in an intensive care setting. 
We included one randomized controlled trial in this review. The overall risk of 
bias was rated as high, and the certainty of the evidence was very low. 
Consequently, we are very uncertain as to whether higher or lower oxygen 
targets should be used to treat mechanically ventilated patients with ARDS. 
Overall completeness and applicability of the 
evidence 
Despite thorough searches, we were only able to identify one completed 
randomized controlled trial investigating how oxygen therapy is targeted and 
administered to patients with ARDS who are receiving invasive mechanical 
ventilation (Barrot 2020). This trial enrolled only 205 participants after which it 
was stopped prematurely, and only two oxygenation targets were compared: 
PaO2 55 to 70 mmHg or SpO2 88% to 92%, and PaO2 90 to 105 mmHg or 
SpO2 ≥ 96%. It is not clear whether these results are generalizeable to all 
patients with ARDS (including those with ARDS secondary to COVID-19). 
Similarly, it is not clear how alternative oxygen targets might affect outcomes 
in patients with ARDS. For example, an intermediate target (e.g. SpO2 92% to 
96%/PaO2 70 to 90 mmHg, or similar range not tested here) could also affect 
clinical outcomes in this group. 
Although the oxygenation targets were well maintained in both groups, other 
factors could also have confounded the apparent mortality benefit in the liberal 
group. Firstly, prone positioning was more frequent in the liberal arm (51% 
versus 34%), and PEEP was higher because ventilation settings were linked 
to the PF ratio in the protocol. Secondly, even though there was no apparent 
difference in the duration of ventilation, because mechanical ventilation was 
defined for follow-up purposes as including other supportive oxygen 
modalities (including non-invasive ventilation and high-flow nasal oxygen), 
one group could potentially still have been extubated earlier than the other. 
Apart from an excess of ischaemic events seen in the conservative group (5 
versus 0), there is no evidence confirming that the excess deaths seen in the 
conservative oxygen group were related to differences in oxygenation. 
The large ICU-ROX study, which randomized 1000 patients receiving 
mechanical ventilation in the intensive care unit to either a conservative or 
usual oxygen therapy, also included a very large prespecified subgroup of 
participants with a PF ratio < 300 mmHg. Although these participants were not 
specified as having a diagnosis of ARDS in the ICU-ROX trial, it is likely that 
many participants in this low PF ratio group would have fulfilled the Berlin 
criteria for ARDS. Conservative oxygen therapy did not significantly alter 
ventilator-free days in ICU-ROX either overall or in the low-PF subgroup, and 
28-day survival was also unaltered overall. However, the definition of 
‘conservative’ in ICU-ROX (SpO2 < 97%) was much closer to the definition of 
‘liberal’ oxygenation in Barrot 2020 (SpO2 ≥ 96%), which makes direct 
comparison difficult. 
We also identified two ongoing studies (yet to report their results) that were 
not eligible for inclusion in this review due to including patients receiving other 
methods of oxygen administration to mechanical ventilation. The handling 
oxygenation targets in the intensive care unit (HOT-ICU) trial is randomizing 
patients with acute respiratory failure to receive oxygen to target a PaO2 of 
either 8 kPa (60 mmHg) or 12 kPa (90 mmHg) (NCT03174002), and the 
second trial is investigating the effects of administering lower amounts of 
oxygen in patients with COVID-19 infection (ChiCTR2000032456). 
Certainty of the evidence 
We downgraded the certainty of the evidence for all outcomes one level for 
risk of bias and two levels for imprecision. Overall, this means that the 
certainty of this evidence remains very low for all outcomes. 
Potential biases in the review process 
We deliberately set out to include the best available evidence for this review, 
and therefore limited the results to only randomized controlled trials. 
Consequently, this may have limited our findings, but has increased the 
reliability of this review. 
We sought the support of two experienced Information Specialists to 
construct, review, and run a sensitive search strategy, and all relevant 
databases and trial registries were searched to identify all relevant trials, both 
those completed and still ongoing. Furthermore, and in contrast to the 
recommended methodology for rapid Cochrane Reviews, all steps of 
reviewing the searches were conducted independently in duplicate by two 
authors experienced at reviewing systematic review search results. Risk of 
bias was also assessed independently in duplicate. 
Although the utility of the evidence is limited by the quantity of studies 
available for inclusion, we believe the review process itself is as robust as it 
could be. 
Agreements and disagreements with other studies or 
reviews 
The data from this review suggest that using a low oxygen target may be 
associated with worse outcomes in mechanically ventilated patients with 
ARDS. Although this is the best available evidence, these findings are notably 
based on one single study and contrast the findings of many recent relevant 
reviews. A previous Cochrane Review assessing the benefits and harms of 
using supplementary oxygen in all patients in an intensive care setting 
identified 10 trials (not including Barrot 2020) with a total of 1285 participants, 
and concluded that mortality may be higher in patients receiving high fractions 
of oxygen (risk ratio (RR) 1.18, 95% CI 1.01 to 1.37) (Barbateskovic 2019). 
However, as with our findings, their conclusions remained uncertain due to 
only being able to identify very low-certainty evidence. Similarly, another 
recent systematic review that aimed to assess the safety and effectiveness of 
high-flow nasal oxygen administration in intensive care also found insufficient 
evidence to do this (Corley 2017), further highlighting the urgent need for 
more certain evidence into how oxygen is used in critical illness. 
Furthermore, our findings also contradict a systematic review and meta-
analysis looking at liberal versus conservative oxygen use in over 16,000 
acutely unwell patients, which demonstrated that liberal oxygen therapy 
(defined as maintaining SpO2 > 96%) significantly increased in-hospital 
mortality (RR 1.21, 95% CI 1.03 to 1.43) and 30-day mortality (RR 1.14, 95% 
CI 1.01 to 1.29) (Chu 2018). Retrospective data looking at associations 
between arterial hyperoxia and mortality in critically ill patients from 17 
separate studies also suggest that hyperoxia is associated with increased 
mortality in patients following cardiac arrest (OR 1.42, 95% CI 1.04 to 1.92), 
stroke (OR 1.23, 95% CI 1.06 to 1.43), and traumatic brain injury (OR 1.41, 
95% CI 1.03 to 1.94) (Damiani 2014). Importantly, this review also concluded 
that data from mechanically ventilated intensive care patients were too 
heterogenous to analyse, primarily due to design flaws and the inconsistent 
definition of hyperoxia. 
As our results were limited to a single paper with high risk of bias, it is not 
appropriate to generalize these findings beyond the scope of the patients with 
ARDS and receiving mechanical ventilation. However, our findings are 
consistent with some international clinical recommendations towards higher 
levels of inspired oxygen in other clinical contexts, which stand in contrast to 
the intensive care and acute illness trial data summarized above. For 
example, the World Health Organization (WHO) recommends administering 
80% oxygen (FiO2 0.8) to all patients undergoing surgery who require 
intubation and anaesthesia in order to reduce the risk of surgical site infection 
(Allegranzi 2016). Notably however, as well as applying to a very different 
group of patients to critically unwell patients with ARDS, this recommendation 
is for all patients to receive a specific inspiratory fraction/concentration of 
oxygen regardless of their individual degree of oxygenation rather than a 
target of oxygenation to aim for. This recommendation also remains 
controversial amongst the anaesthetic community following previous 
Cochrane Reviews and evidence from other perioperative trials (Meyhoff 
2008; Myles 2019; Oldman 2019; Wetterslev 2015). Importantly, this 
recommendation also only considers evidence focused on reducing surgical 
site infections and does not consider how any other outcomes (including those 
more relevant in a critical care context, such as mortality) may be affected by 
oxygen administration. 
This rapid review highlights the profound limitations in volume and quality of 
studies evaluating oxygen targets in mechanically ventilated patients with 
ARDS. There remains considerable controversy surrounding oxygen across 
perioperative, acute medical, and intensive care literature, and this review 
serves to highlight where future trial efforts need to be focused. 
Authors' conclusions 
The currently available evidence on targeting oxygen administration in 
patients with ARDS and receiving invasive mechanical ventilation is of very 
low certainty. Consequently, all conclusions drawn from these data are of 
limited value to clinicians and may change with further updates of this review 
as and when more evidence becomes available. The one study included in 
this review reported that participants receiving supplemental oxygen to target 
a PaO2 = 90 to 105 mmHg or SpO2 ≥ 96% were more likely to survive beyond 
90 days than those who received oxygen targeted towards achieving either 
PaO2 = 55 to 70 mmHg or SpO2 = 88% to 92%, but the certainty of the 
evidence for this finding was very low. We are also very uncertain how oxygen 
targets affect  duration of mechanical ventilation, catecholamine use, or use of 
renal replacement therapy in these patients. Further randomized controlled 
trials, including studies investigating different oxygen targets not tested here, 
are urgently needed to add more certainty to these findings and assess how 
best to target oxygen administration in mechanically ventilated patients with 
ARDS. 
What's new 
Date Event Description 
12 October 2020 Amended Changed review type to 'Rapid (Flexible review)' 
History 
Review first published: Issue 9, 2020 
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Differences between protocol and review 
All differences to the original protocol (i.e. the inability to assess for 
heterogeneity or to perform a separate subgroup analysis for studies 
specifically in patients with ARDS secondary to COVID-19 or other viruses 
due to only finding one eligible study) have already been detailed and 
explained within the main text of the review. 
Characteristics of studies 




Methods Randomized controlled trial 
Multicentre 
Participants 
Sample size: conservative, n = 99,  liberal, n = 102 
Sex (male): conservative 65.7%, liberal 62.7% 
Age (mean): conservative 63.0, liberal 63.5 
Country: France 
Setting: adults who had undergone intubation and had been receiving 
mechanical ventilation for less than 12 hours for ARDS (according to the 
Berlin definition) 
Disease severity score: SAPS III median 67.5, SOFA median 9.1 
Inclusion criteria 
1. Major patients with mechanical ventilation 
2. ARDS according to Berlin definition: hypoxaemia defined with 
PaO2/FiO2 ratio less or equal to 300 mmHg with positive end-
expiratory pressure higher or equal to 5 cmH2O, Less than 7 
days between a known clinical insult or new or worsening of 
respiratory symptoms; bilateral opacities on chest imaging not 
fully explained by effusions, lobar or lung collapse, or nodules; 
respiratory failure not fully explained by cardiac failure or fluid 
overload 




2. Patient less than 18 years old 
3. Sickle cell disease 
4. Patient deprived of freedom, under a legal protective measure 
5. Cardiac arrest as the reason for ICU hospitalization 
6. Traumatic brain injury as the reason for ICU hospitalization 
7. Haemoptysis with embolization or surgery 
8. Extracorporeal life support or extracorporeal membrane 
oxygenation before randomization 
9. Chronic obstructive pulmonary disease with oxygen or non-
invasive ventilation at home (obstructive sleep apnoea 
syndrome is not an exclusion criterion) 
10. Patient with very high risk of death with SAPS II more than 90 
11. Indication of hyperbaric oxygenation: carbon monoxide 
intoxication, gas embolism, necrotizing fasciitis 
12. Cyanide intoxication, methaemoglobinaemia 
13. Untreated pneumothorax 
14. Lymphangitis carcinomatosa 
15. Eosinophilic pneumonia 
16. Intensive care management for organ donation 
17. Participation in another interventional study with mortality as a 
major outcome to avoid confounding factor 
18. Patient not affiliated to social security 
Interventions 
Experimental (conservative): a modulation of inspired fraction of oxygen 
will be performed with an objective of PaO2 between 55 to 70 mmHg that 
will be checked on arterial blood gases. Between these measurements, 
SpO2 will be kept between 88 and 92 per cent. Alarms will be set between 
87 and 93 per cent for SpO2. 
Control (liberal): a modulation of inspired fraction of oxygen will be 
performed with an objective of PaO2 between 90 to 105 mmHg that will be 
checked on arterial blood gases. Between these measurements, SpO2 will be 
kept more or equal to 96 per cent. Alarms will be set at 95 per cent for 
SpO2. 
 Primary outcome measures: 
1. Death [ Time Frame: Day 28 ] 
Secondary outcome measures: 
1. Death [ Time Frame: Day 90 ] 
2. Days free of mechanical ventilation in ICU [ Time Frame: Day 
28 ] 
3. Sequential Organ Failure Assessment (SOFA) score without 
the respiratory component (i.e. maximum score of 20) [ Time 
Frame: Day 0, 3, and 7 ].  
a. The SOFA score is the association of the organ failure 
score of the six following systems: respiratory, 
cardiovascular, renal, liver, coagulation and neurologic. 
In each system a progressive score of gravity is 
attributed from 0 to 4 giving a maximum possible total 
of 24. Without the addition of the respiratory component 
the score has a maximum of 20, with a higher number 
representing a higher severity of illness. 
4. Score of morbidity [ Time Frame: Day 28 ] 
a. This score is based on three points: need for 
mechanical ventilation, need for Morbidity are renal 
replacement therapy, need of catecholamine or need 
for ventilation 
5. Ventilator-associated pneumonia [ Time Frame: Day 28 ] 
6. Septicaemia [ Time Frame: Day 28 ] 
7. Antibiotic consumption [ Time Frame: Day 28 ] 
a. Defined as number of days exposed to antibiotics 
divided by the number of days spent in ICU 
8. Cardiovascular complications [ Time Frame: Day 28 and 90 ] 
a. Defined as new onset of rhythm disorders, cardiac 
ischaemia and dose of catecholamine at 28 and 90 
days 
9. Neurological evolution [ Time Frame: Day 28 ] 
a. Defined as neurological evolution measured with daily 
Richmond Agitation Sedation Scale score, seizures, 
new stroke, daily sedation doses, neuroleptic 
administration 
10. Respiratory autonomy [ Time Frame: Day 28 and 90 ] 
a. Defined as need for oxygen or mechanical ventilation 
support 
Notes Trial was funded by public grants.  





Randomization was stratified according to center, age (<45 
years, 45 to 65 years, or >65 years), and severity of respiratory 
failure evaluated according to the Pao2:Fio2 (≤150 mm Hg or 
>150 mm Hg), with a PEEP of 5 cm of water and a Fio2. 










This was an open-label trial because of the impossibility of 
masking treatment assignments with the use of Spo2 and Pao2 






This was an open-label trial because of the impossibility of 
masking treatment assignments with the use of Spo2 and Pao2 




Yes 4% in the experimental group and none of the control group were excluded from the analysis 
Selective reporting 
(reporting bias) Yes 
The trial was registered prior to randomisation 
(NCT02713451) 
Other bias No 
Early stopping bias: the trial was stopped after a pre‐planned 
trial safety committee meeting, criteria for stopping not 
specified 
[2] ARDS: acute respiratory distress syndrome, cmH2O: centimetre of water, FiO2: fraction of 
inspired oxygen, ICU: intensive care unit, PaO2: arterial partial pressure of oxygen SAPS: 
simplifed acute physiology score, SOFA: sequential organ failure assessment, SpO2: peripheral 
oxygen saturation 
Characteristics of excluded studies [ordered by study 
ID] 
Study Reason for exclusion 
ChiCTR2000032456 Ongoing trial yet to be published; wrong study population 
NCT03174002 Ongoing trial yet to be published; wrong study population 
Appendices 
Appendix 1. Protocol 
Criteria for considering studies for this review 
Study and source eligibility 
Study design ☒ RCTs 
☐   Quasi-RCTs 
☐   Non-RCTs 
☐ Prospective cohort studies 
☐   Retrospective cohort studies 
☐   Case-control studies 
☐   Cross-sectional studies 
☐   Controlled before-and-after studies 
☐   Modelling studies 
☐   Other (please specify) 
Minimum 
duration 
No minimum duration 
‘PICO’ eligibility 
Population •  
o Inclusion criteria 
 Adults (> 18) 
 Admitted to an intensive care unit / critical care unit / 
level 3 care facility 
 Receiving mechanically ventilation via an 
endotracheal tube or tracheostomy 
 acute respiratory distress syndrome (Berlin 
definition) 
o Exclusion criteria 
 Non-invasive ventilation only 
 High-flow nasal oxygen only 
 Hyperbaric oxygen 
 ECMO 
 Cardiac bypass 
Intervention(s) Liberal’ oxygen (defined only as relative to conservative/control group to 
maximize inclusion of studies and may consist of targeting higher SpO2, PaO2, 
or any combination of these where the study intention is to compare groups 
receiving different amounts of oxygen (in the opinion of the authors)   
Comparator(s) ‘Conservative’ oxygen - defined only that the study intention (in the opinion of 
the review authors) is to compare giving a lower amount of oxygen to this group 
than the intervention arm in the trial. This may be targeting mild hyperoxaemia 
(but still less than the intervention arm in the same study targeting a higher 
degree of hyperoxaemia), normoxaemia, or hypoxaemia. 
Outcome(s) The following outcomes will be examined. 
• Mortality at longest available follow-up 
• Number of days ventilated 
• Requirement for inotropic support 
• Requirement for renal replacement therapy 
• Quality of life (any recognized scale as reported by trialists) 
Search methods for identification of studies 
Search methods 
Expertise The searches will be verified by a content expert, conducted by an 
Information Specialist, and independently peer reviewed. 
Electronic databases Database [minimum checked – 




☒ Other - Cochrane COVID-19 
Study Register 






Other searches ☒ Systematic review references 
☒ Reference lists of included 
studies 
☐ Grey literature (please specify) 
☐ Citation tracking 
☐ Data from the pharmaceutical 
industry 
☐ Contact experts for references 
☐ Other (please specify) 
 
Approach to ongoing 
and unpublished 
studies 
☐ Include ongoing studies 
☐ Unpublished studies 
☐ Studies in press 
☒ Exclude all studies that are 
ongoing, unpublished, or in press 
Through handsearching references 
and including ongoing trials across 
major databases 
Methods for screening search results 
Expertise Screening will be performed by AO/AC 
Screening methods Dual; second reviewer checks all 
excluded records 
Dual; second reviewer 
checks [X%] of excluded records 












☒ Consensus and/or third reviewer 
☐Other (please specify) 
Excluded studies All decisions taken during full-text screening will be documented and 
outlined in the final report with a list of excluded studies. 
Inclusion of abstracts 
and conference 
proceedings 
☐ Exclude all 
☒ Include if clearly eligible and have useable data 
☐ Include if clearly eligible regardless of useable data 




☒ Include abstracts and full texts [in Chinese/any language] 
☐ Include full texts only [in Chinese only/ language] 
☐ Exclude 
☒ All potentially relevant abstracts will progress to full-text screen 
☐ [Single/dual] title/abstract screen by foreign-language speaker(s) 
☒ [Abstract/methods/full text] will be translated for abstract/full 
text screen 
☐ Listed as non-English language and not assessed further 
Data collection and analysis 
Data extraction 
Expertise Data extraction will be performed by AO and AC 
Software Data will be extracted using pilot-tested data extraction forms through the 
online resource: Rayyan Systematic Review software 
Data to be 
extracted 




☐ Single, no second reviewer 
☒ Dual; second reviewer checks all data 
☐ Dual; second reviewer checks [add proportion] 
☐ Dual; independent screen and cross check 
Risk of bias tool [specify for each study design] 
☒ Cochrane 'Risk of bias' tool (RCTs) 
☐ ROBINS-I tool for non-randomized studies 
☐ Adapted-hybrid of the RCT-ROBINS-I tools 
☐ Newcastle-Ottawa Scale 
☐ Another tool [please specify] 
Method of risk of 
bias assessment 
☐ Single, no second reviewer 
☒ Dual; second reviewer checks all judgements 
☐ Dual; second reviewer checks [add proportion] 
☐ Dual; independent screen and cross check 
☐ All outcomes 
☐ Primary only 
Discrepancy 
resolution 
☒ Consensus and/or third reviewer 
☐ Other (please specify) 
Contacting study 
authors 
☐ Authors will be contacted for missing information and data 
☒ Authors will be contacted for missing outcome data only 
☐ Authors will not be contacted 
Data management 





If there is a conflict between data reported across multiple sources for a 
single study (e.g. between a published article and a trial registry record), we 




☒ Continuous outcome: mean difference and 95% confidence intervals (CIs) 
☒ Continuous outcome: standardized mean difference 
☐ Dichotomous outcome: risk ratio/relative risk (RR) and 95% CIs 
☒ Dichotomous outcome: odds ratio (OR) and 95% CIs 
☐ Dichotomous outcome: risk difference (absolute risk reduction) 
☐ Peto odds ratio method 
☐ Other (please specify) 
[Any data processing required will be performed in accordance with 
the Cochrane Handbook for Systematic Reviews of Interventions] 
Unit of analysis 
issues 
Advice from a statistician will be sought to address issues relating to double 
counting, correlation or unit of analysis posed by the following. 
☒ Cluster RCTs 
☐ Cross-over trials 
☐ Body-part randomized trials 
☒ Episodes of disease 
☒ Multi-arm studies 
☐ Other (please specify) 
Assessment of 
heterogeneity 
☒ Inspecting forest plots 
☐ Statistical test (Chi2) for heterogeneity [specify P value] 
☒ I2 statistic [state how values of I2 will be interpreted] 
☒ Explore potential sources of the heterogeneity amongst study results 
☐ Sensitivity analysis by excluding outlying studies 
 
(THIS WILL REQUIRE CLARIFICATION WITH STATISTICIAN) 
Assessment of 
reporting biases 
☒ Funnel plots 
☒ Test for funnel plot asymmetry (e.g. Begg, Egger test) 
☐ Trim and fill technique 
Data synthesis ☒ Forest plots 
☒ Qualitative synthesis 
☐ Synthesis without meta-analysis 
[Specify data type and study designs, interventions to be pooled 
If non-randomized and observational studies are included, describe how 
these studies will be analysed] 
Model ☐ Fixed-effect meta-analyses 
☒ Random-effects meta-analyses (DerSimonian and Laird method) 
☐ Other [please specify] 
Subgroup analyses The following subgroups will be explored. 
• If sufficient studies exploring acute respiratory distress 
syndrome specifically following COVID-19 (or other similar viral 
infections) are available, then these will be analysed and 
considered separately. 
• In the event of intervention and comparator groups of included 
studies inadvertently overlapping if different criteria are used 
by different studies to define oxygenation target groups, 
different subgroups of studies with similar target groups will be 
considered separately. If this approach becomes necessary 
following searches, subgroup boundaries/limits will be 




☐ Excluding studies at high risk of bias 
☐ Excluding studies with dubious eligibility 
☐ Alternative analysis methods [specify] 
☐ Other [please specify] 
Any post hoc sensitivity analyses that arise during the review process will be 
justified in the final report. 
GRADE approach ☒ GRADE will be used for [all outcomes/the primary outcome(s)] and 
results presented in a 'Summary of findings' table 
Appendix 2. Search strategies 
Database: Ovid MEDLINE(R) ALL <1946 to May 14, 2020> 
1     Respiratory Distress Syndrome, Adult/ 
2     exp Severe Acute Respiratory Syndrome/ 
3     (ards or sars).ti,ab,kf. 
4     (acute respiratory adj2 (syndrome* or distress or failure*)).ti,ab,kf. 
5     ((acute or adult or syndrome*) adj2 respiratory distress).ti,ab,kf. 
6     exp coronavirus/ 
7     exp Coronavirus Infections/ 
8     (coronavirus* or corona virus* or Covid 19 or Covid19 or SARS CoV* or 
SARSCov* or ncov* or 19ncov*).ti,ab,kf. 
9     6 or 7 or 8 
10     9 and (201912* or 2020*).dt. 
11     1 or 2 or 3 or 4 or 5 or 10 
12     Oxygen/ad, sd, th 
13     exp Oxygen-Inhalation-Therapy/ 
14     exp Hyperoxia/ 
15     Hypoxia/ 
16     (hyperoxia or hyperoxemia or hyperoxaemia or hypoxia or hypoxemia or 
hypoxaemia or anoxia or anoxemia or anoxaemia or high* oxygen or 
oxygenat* or blood gas* or pao2 or sao2 or spo2).ti,ab,kf. 
17     ((inspir* or inhal* or fraction* or concentrat* or arterial* or saturation or 
level* or tension* or supply* or supplement* or supplie* or therap* or 
administr* or dosag* or dose* or dosing* or conservative or liberal or 
restrictive or partial pressure) adj3 oxygen).ti,ab,kf. 
18     12 or 13 or 14 or 15 or 16 or 17 
19     exp Respiration, Artificial/ 
20     (artificial* adj3 respirat*).ti,ab,kf. 
21     ventilat*.ti,ab,kf. 
22     19 or 20 or 21 
23     11 and 18 and 22 
24     ((randomized controlled trial or controlled clinical trial).pt. or 
randomi?ed.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or trial.ab. 
or groups.ab.) not (exp animals/ not humans.sh.) 
25     23 and 24 
Database: Embase <1974 to 2020 May 14> 
1     adult respiratory distress syndrome/ 
2     severe acute respiratory syndrome/ 
3     (ards or sars).ti,ab,kw. 
4     (acute respiratory adj2 (syndrome* or distress or failure*)).ti,ab,kw. 
5     ((acute or adult or syndrome*) adj2 respiratory distress).ti,ab,kw. 
6     exp coronavirinae/ 
7     exp coronaviridae infection/ 
8     (coronavirus* or corona virus* or Covid 19 or Covid19 or SARS CoV* or 
SARSCov* or ncov* or 19ncov*).ti,ab,kw. 
9     6 or 7 or 8 
10     9 and (201912* or 2020*).dc. 
11     1 or 2 or 3 or 4 or 5 or 10 
12     exp oxygen therapy/ 
13     hyperoxia/ 
14     hyperoxia-induced lung injury/ 
15     exp hypoxemia/ 
16     (hyperoxia or hyperoxemia or hyperoxaemia or hypoxia or hypoxemia or 
hypoxaemia or anoxia or anoxemia or anoxaemia or high* oxygen or 
oxygenat* or blood gas* or pao2 or sao2 or spo2).ti,ab,kw. 
17     ((inspir* or inhal* or fraction* or concentrat* or arterial* or saturation or 
level* or tension* or supply* or supplement* or supplie* or therap* or 
administr* or dosag* or dose* or dosing* or conservative or liberal or 
restrictive or partial pressure) adj3 oxygen).ti,ab,kw. 
18     12 or 13 or 14 or 15 or 16 or 17 
19     exp artificial ventilation/ 
20     (artificial* adj3 respirat*).ti,ab,kw. 
21     ventilat*.ti,ab,kw. 
22     19 or 20 or 21 
23     (randomized controlled trial/ or controlled clinical study/ or 
random$.ti,ab. or randomization/ or intermethod comparison/ or placebo.ti,ab. 
or (compare or compared or comparison).ti. or ((evaluated or evaluate or 
evaluating or assessed or assess) and (compare or compared or comparing 
or comparison)).ab. or (open adj label).ti,ab. or ((double or single or doubly or 
singly) adj (blind or blinded or blindly)).ti,ab. or double blind procedure/ or 
parallel group$1.ti,ab. or (crossover or cross over).ti,ab. or ((assign$ or match 
or matched or allocation) adj5 (alternate or group$1 or intervention$1 or 
patient$1 or subject$1 or participant$1)).ti,ab. or (assigned or allocated).ti,ab. 
or (controlled adj7 (study or design or trial)).ti,ab. or (volunteer or 
volunteers).ti,ab. or human experiment/ or trial.ti.) not (((random$ adj sampl$ 
adj7 (cross section$ or questionnaire$1 or survey$ or database$1)).ti,ab. not 
(comparative study/ or controlled study/ or randomi?ed controlled.ti,ab. or 
randomly assigned.ti,ab.)) or (cross-sectional study/ not (randomized 
controlled trial/ or controlled clinical study/ or controlled study/ or randomi?ed 
controlled.ti,ab. or control group$1.ti,ab.)) or (((case adj control$) and 
random$) not randomi?ed controlled).ti,ab. or (Systematic review not (trial or 
study)).ti. or (nonrandom$ not random$).ti,ab. or Random field$.ti,ab. or 
(random cluster adj3 sampl$).ti,ab. or ((review.ab. and review.pt.) not trial.ti.) 
or (we searched.ab. and (review.ti. or review.pt.)) or update review.ab. or 
(databases adj4 searched).ab. or ((rat or rats or mouse or mice or swine or 
porcine or murine or sheep or lambs or pigs or piglets or rabbit or rabbits or 
cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or 
marmoset$1).ti. and animal experiment/) or (Animal experiment/ not (human 
experiment/ or human/))) 
24     11 and 18 and 22 and 23 
Central 
Issue 5 of 12, May 2020 
#1            MeSH descriptor: [Respiratory Distress Syndrome, Adult] explode 
all trees 
#2            MeSH descriptor: [Severe Acute Respiratory Syndrome] explode all 
trees 
#3            (ards or sars):ti,ab,kw 
#4            ((acute next respiratory) near (syndrome* or distress or 
failure*)):ti,ab,kw 
#5            ((acute or adult or syndrome*) near (respiratory next 
distress)):ti,ab,kw 
#6            MeSH descriptor: [Coronavirus] explode all trees 
#7            MeSH descriptor: [Coronavirus Infections] explode all trees 
#8            (coronavirus* or (corona next virus*) or (Covid next 19) or Covid19 
or (SARS next CoV*) or SARSCov* or ncov* or 19ncov*):ti,ab,kw 
#9            #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 
#10          MeSH descriptor: [Oxygen] explode all trees 
#11          MeSH descriptor: [Oxygen Inhalation Therapy] explode all trees 
#12          MeSH descriptor: [Hyperoxia] explode all trees 
#13          MeSH descriptor: [Hypoxia] explode all trees 
#14          (hyperoxia or hyperoxemia or hyperoxaemia or hypoxia or 
hypoxemia or hypoxaemia or anoxia or anoxemia or anoxaemia or (high* next 
oxygen) or oxygenat* or (blood next gas*) or pao2 or sao2 or spo2):ti,ab,kw 
#15          ((inspir* or inhal* or fraction* or concentrat* or arterial* or saturation 
or level* or tension* or supply* or supplement* or supplie* or therap* or 
administr* or dosag* or dose* or dosing* or conservative or liberal or 
restrictive or (partial next pressure)) near oxygen):ti,ab,kw 
#16          #10 or #11 or #12 or #13 or #14 or #15 
#17          MeSH descriptor: [Respiration, Artificial] explode all trees 
#18          (artificial* near respirat*):ti,ab,kw 
#19          ventilat*:ti,ab,kw 
#20          #17 or #18 or #19 
#21          #9 and #16 and #20                
#22          #21 in Trials 
Cochrane Covid-19 study register 
Filtered by: 
oxygen or hyperoxia or hyperoxemia or hyperoxaemia or hypoxia or 
hypoxemia or hypoxaemia or anoxia or anoxemia or anoxaemia or oxygenat* 
or "blood gas" or pao2 or sao2 or spo2 
AND 
ventilat* or respirat* 
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